Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
never use stoplosses on OTC, especially when the share price has been so volatile!
beautifull action so far, following the TA in sync.
glad I had an order in at .98
2-73 plus still outstanding
This would be an awesome one to have.
We remember TPIV, so far the similiarity on charts still stand
And don't forget that INO's CFO has left to seek other challenges, aka pushed out. Oh wait, that was Punit Dhillon.
Disregard please, iphone typo
I am waiting. Do believe it will retest the .95 area. It was rather a big resistance on the way up so should give quite some support too. Lets hope it holds.
According my memory you claimed last week we would never see this levels again. You even called me out.
Hang in there, it will pay off in the long run. Inovio has not been receiving much market love lately, but it is setting itself up for great success. Just look at the DARPA deal on mAbs!
I like your humour.
Well patience is always a trade off. You invest in the science but as an investor you like to see a return on investment. If it takes too long me too start wondering about investment opportunity and wether I should invest in some other company and come back later.
I have done just that: bought into ARCH and had it from .20 to .32. I still keep track of ARch and will get back into at some stage, probably towards end of q3
Up 15%
Ouch
Ouch, pps rises 15%, tutes showed up to show support.
Hysterically funny, dont you reckon?
Remember that 8$ really is only 2$ pre-RS. It ran to 3.86$ early last year. Based on todays news we should be valued a lot higher.
Such a pity Afuckerstein is on holiday!
Down 10% on triple daily volume. Reason in latest 10q and human trials only in q4?
And in the meantime ONCS is up by 13%, on the back of INO?
Well I guess one is pleased easier then another.
But lets continue the talk on Veronica, I have missed the interesting chats on her
Sure he did, you must know the pr by now
From Christine:
Thank you for your email and continued interest in Anavex Life Sciences Corp. (OTCQX: AVXL).
The amount of the grant from the Michael J. Fox Foundation for Parkinson’s Research was not disclosed. The press release does however state that it is expected to fully fund the preclinical study.
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
Christine Payne
I did on twitter, but no response (yet)
thats excellent news, increase exposure!
So how much is the grant?
Why is that not mentioned in the pr?
the market must be having an off day, otherwise it would not allow ONCS to rise ;)
Am I on the wrong board or are you?
Sorry the funding is for preclinical ik animals, not a human p1
No figure mentioned
How much is a preclinical study usually? Couple of hundred grant?
Not so reliable yet cause the volume is too low. But it will be a great day!
We peaked to 14 in July last year on vgx3100 data. So we still have a way to go and recover.
VGX-3100 paper, with full data, has been accepted for publication by peer reviewed journal!
Little late, by 1 year, but still good news
I was thinking exactly the same when the CFO resigned.
Roche deal = 10 mil upfront and 412,5 mil in milestones
MeddImune deal = 27,5 mil upfront and 700 mil in milestones
Excellent news for Inovio, and at better conditions that Roche offered.
MedImmune is no stranger to INO as they are already working together as part of the DARPA grant.
INOVIO PHARMACEUTICALS ENTERS INTO STRATEGIC CANCER VACCINE COLLABORATION AND LICENSE AGREEMENT WITH MEDIMMUNE
Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates
Inovio schedules conference call for 8:30am ET today;Go to inovio.com and click on “webcast” tab
PLYMOUTH MEETING, Pa. – August 10, 2015 – Inovio Pharmaceuticals (NASDAQ: INO) today announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.
Under the agreement, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70 percent of cervical pre-cancers and cancers.
MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging evidence suggests that the benefits from immuno-oncology molecules, such as those in MedImmune’s portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells.
Under the terms of the agreement, MedImmune will make an upfront payment of $27.5 million to Inovio as well as potential future payments upon reaching development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. Inovio is entitled to receive up to double-digit tiered royalties on INO-3112 product sales.
Within the broader collaboration, MedImmune and Inovio will develop up to two additional DNA-based cancer vaccine products not included in Inovio’s current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. Inovio will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales for these additional cancer vaccine products.
Dr. David Berman, Senior Vice President and Head of the Oncology Innovative Medicines unit, MedImmune, said: “Today’s collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-specific T-cell responses. The unique combination of our broad immuno-oncology portfolio with Inovio’s T-cell-activating INO-3112, which enhances cancer specific killer T-cells, has the potential to deliver real clinical benefits for patients.”
Dr. J. Joseph Kim, President and CEO, Inovio, said: “Our licensing partnership with MedImmune represents an important step in executing our immuno-oncology combination strategy and advancing Inovio’s cancer vaccine R&D pipeline with a leading cancer immunotherapy company. INO-3112 is progressing, with positive interim data generated in an Inovio-initiated phase I study. We appreciate MedImmune’s recognition of our ability to activate best-in-class killer T-cells in vivo and look forward to working with them on this collaboration.”
Today’s agreement builds on the existing partnership between Inovio and MedImmune on two research and development collaborations in the infectious disease area. Both efforts are funded by the Defense Advanced Research Projects Agency (DARPA) and support R&D focused on Ebola, influenza, and bacterial infections. MedImmune has a strong heritage in infectious disease and vaccine innovation, having developed the first monoclonal antibody approved by the US Food & Drug Administration for the prevention of an infectious disease and the technology that led to the creation of an HPV vaccine.
About INO-3112
Inovio's SynCon® DNA-based immunotherapies help the immune system activate disease-specific killer T cells to fight a targeted disease. HPV, the most pervasive sexually transmitted virus, causes numerous pre-cancers and cancers. Inovio's HPV immunotherapy called INO-3112 targets disease associated with the high-risk HPV types 16 and 18, which are responsible for over 70% of cervical pre-cancers and cancers. INO-3112 combines Inovio’s VGX-3100, its immunotherapy targeting HPV-caused diseases, with its DNA-based immune activator encoded for IL-12. INO-3112 is in three clinical studies for cervical and head and neck cancers.
Earlier this year, Inovio reported preliminary data showing that INO-3112 generated significant antigen-specific CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. These positive results represent the first study and first report of antigen-specific T cell immune responses generated in cancer patients after treatment with a DNA immunotherapy.
Previously in a phase II efficacy trial, treatment with VGX-3100 resulted in histopathological regression of late-stage cervical dysplasia to early stage or no disease, meeting the study's primary endpoint. In addition, the trial demonstrated clearance of the HPV virus in conjunction with regression of cervical lesions, meeting the secondary endpoint. Robust T-cell activity was observed in subjects who received VGX-3100 compared to those who received placebo.
About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers. For more information, please visit www.medimmune.com.
About AstraZeneca in Oncology
Oncology is a therapeutic area in which AstraZeneca has a deep-rooted heritage. It will be potentially transformational for the company’s future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.
Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and hematological cancers. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
That is tru DD-dedication Wolf!
thank you
It's a good thing that the market is always right! ;)
I have had no time to go through it. Did anybody find anything new in it?
You fail to respond to the points raised. It seems all your saying is that your are saying because you have 551k @.20 that you are smarter
I am not at all arguing on the science. I am saying that lots still need to happen to get an approved drug and that lots could still go wrong. So too early to count the chickens yet.
Sorry but I disagree with you. Not wanting to see that we are not in an endstage yet could be explained as soft pumping too.
Yes the data we have so far is excellent but very limited. 12 patients is nothing in the big scheme. It will all have to be replicated and confirmed on a bigger scale before we can blow the victory horn.
Keeping your expectations realistic is a smart investor tactic.
Too many people on this board are dreaming on how to spend their millions
Oh I wouldn't be trading this stock, way to unpredictable! But I will add on dips.
But i believe pps will only sustain on further news
My gut feeling tells me that in the absence of further news in the next couple of weeks, pps support will not hold. Too much manipulation to get in cheaper.